BRCAness: a deeper insight into basal-like breast tumors.

No abstract is available for this paper.

• Publication year

  2013

• Venue

  Annals of Oncology

• Publication date

  2013-11-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1093/annonc/mdt306PMID 24131964
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Synthetic lethal targeting of DNA double‐strand break repair deficient cells by human apurinic/apyrimidinic endonuclease inhibitors

  2012influential reference
• Acetylation on critical lysine residues of Apurinic/apyrimidinic endonuclease 1 (APE1) in triple negative breast cancers.

  2012cited by this paper
• Methylation of O6-methylguanine-DNA methyltransferase (MGMT) promoter gene in triple-negative breast cancer patients

  2012cited by this paper
• Differential anti-proliferative activities of poly(ADP-ribose) polymerase (PARP) inhibitors in triple-negative breast cancer cells

  2012cited by this paper
• Small-molecule inhibitors of APE1 DNA repair function: an overview.

  2012cited by this paper
• PARP-1 expression in breast cancer including BRCA1-associated, triple negative and basal-like tumors: possible implications for PARP-1 inhibitor therapy

  2011cited by this paper
• A randomized phase III study of iniparib (BSI-201) in combination with gemcitabine/carboplatin (G/C) in metastatic triple-negative breast cancer (TNBC).

  2011cited by this paper
• Basal-like Breast cancer DNA copy number losses identify genes involved in genomic instability, response to therapy, and patient survival

  2011cited by this paper
• Metastatic triple-negative breast cancer.

  2011cited by this paper
• Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies.

  2011influential reference
• miR-182-mediated downregulation of BRCA1 impacts DNA repair and sensitivity to PARP inhibitors.

  2011cited by this paper
• Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: a proof-of-concept trial

  2011cited by this paper
• Iniparib plus chemotherapy in metastatic triple-negative breast cancer.

  2011cited by this paper
• A review of PARP inhibitors: from bench to bedside.

  2011cited by this paper
• Development and evaluation of human AP endonuclease inhibitors in melanoma and glioma cell lines

  2011cited by this paper
• Evaluation of O6-methylguanine-DNA methyltransferase by immunohistochemistry: best clinical and research practices.

  2011cited by this paper
• Unmeasured costs of a child's death: perceived financial burden, work disruptions, and economic coping strategies used by American and Australian families who lost children to cancer.

  2011cited by this paper
• BRCA1-mutated and basal-like breast cancers have similar aCGH profiles and a high incidence of protein truncating TP53 mutations

  2010cited by this paper
• Subtypes of familial breast tumours revealed by expression and copy number profiling

  2010cited by this paper
• PARP inhibition: PARP1 and beyond

  2010cited by this paper
• Genome Remodeling in a Basal-like Breast Cancer Metastasis and Xenograft

  2010cited by this paper
• Radiation resistance in glioma cells determined by DNA damage repair activity of Ape1/Ref-1.

  2010cited by this paper
• Protein expression profile and prevalence pattern of the molecular classes of breast cancer - a Saudi population based study

  2010cited by this paper
• Critical lysine residues within the overlooked N-terminal domain of human APE1 regulate its biological functions

  2010cited by this paper
• BARD1 homozygous deletion, a possible alternative to BRCA1 mutation in basal breast cancer

  2010cited by this paper
• MGMT expression levels predict disease stabilisation, progression-free and overall survival in patients with advanced melanomas treated with DTIC.

  2010cited by this paper
• Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer: a proof-of-concept trial.

  2010cited by this paper
• Transcriptional Regulation of the Base Excision Repair Pathway by BRCA1*

  2010cited by this paper
• Upregulation of Poly (ADP-Ribose) Polymerase-1 (PARP1) in Triple-Negative Breast Cancer and Other Primary Human Tumor Types.

  2010cited by this paper
• Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: a proof-of-concept trial.

  2010cited by this paper
• Androgen receptor in breast cancer: expression in estrogen receptor-positive tumors and in estrogen receptor-negative tumors with apocrine differentiation

  2010cited by this paper
• High incidence of protein-truncating TP53 mutations in BRCA1-related breast cancer.

  2009cited by this paper
• Extent of MGMT promoter methylation correlates with outcome in glioblastomas given temozolomide and radiotherapy

  2009cited by this paper
• The prevalence of BRCA1 mutations among young women with triple-negative breast cancer

  2009cited by this paper
• Defective repair of oxidative dna damage in triple-negative breast cancer confers sensitivity to inhibition of poly(ADP-ribose) polymerase.

  2009influential reference
• Long-term survival of patients with glioblastoma treated with radiotherapy and lomustine plus temozolomide.

  2009cited by this paper
• Ki67 Index, HER2 Status, and Prognosis of Patients With Luminal B Breast Cancer

  2009cited by this paper
• Synthetic lethal targeting of PTEN mutant cells with PARP inhibitors

  2009cited by this paper
• Evidence that inositol polyphosphate 4-phosphatase type II is a tumor suppressor that inhibits PI3K signaling.

  2009cited by this paper
• High frequency of TP53 mutation in BRCA1 and sporadic basal-like carcinomas but not in BRCA1 luminal breast tumors.

  2009cited by this paper
• HER-2 overexpression/amplification and its interaction with taxane-based therapy in breast cancer.

  2008cited by this paper
• Impact of Triple Negative Phenotype on Breast Cancer Prognosis

  2008cited by this paper
• How basal are triple‐negative breast cancers?

  2008cited by this paper
• High‐resolution genomic and expression analyses of copy number alterations in breast tumors

  2008cited by this paper
• The role of hormonal therapy in the management of hormonal-receptor-positive breast cancer with co-expression of HER2

  2008cited by this paper
• Epidemiology of basal-like breast cancer

  2008cited by this paper
• Recurrent gross mutations of the PTEN tumor suppressor gene in breast cancers with deficient DSB repair

  2008cited by this paper
• Biologic and clinical characteristics of breast cancer with single hormone receptor positive phenotype.

  2007cited by this paper
• BRCA1 dysfunction in sporadic basal-like breast cancer

  2007cited by this paper
• Integrated profiling of basal and luminal breast cancers.

  2007cited by this paper
• Identification of conserved gene expression features between murine mammary carcinoma models and human breast tumors

  2007cited by this paper
• Triple-Negative Breast Cancer: Clinical Features and Patterns of Recurrence

  2007cited by this paper
• Moesin expression is a marker of basal breast carcinomas

  2007cited by this paper
• Emergence of a DNA-damage response network consisting of Fanconi anaemia and BRCA proteins

  2007cited by this paper
• Caveolin 1 Is Overexpressed and Amplified in a Subset of Basal-like and Metaplastic Breast Carcinomas: A Morphologic, Ultrastructural, Immunohistochemical, and In situ Hybridization Analysis

  2007cited by this paper
• Gene expression profiling and histopathological characterization of triple-negative/basal-like breast carcinomas

  2007cited by this paper
• Cellular functions of the BRCA tumour-suppressor proteins.

  2006cited by this paper
• Catechol Quinones of Estrogens in the Initiation of Breast, Prostate, and Other Human Cancers

  2006influential reference
• Caveolin-1 expression is associated with a basal-like phenotype in sporadic and hereditary breast cancer

  2006cited by this paper
• Clinicopathologic significance of the basal-like subtype of breast cancer: a comparison with hormone receptor and Her2/neu-overexpressing phenotypes.

  2006cited by this paper
• Prognostic Significance of Basal-Like Phenotype and Fascin Expression in Node-Negative Invasive Breast Carcinomas

  2006cited by this paper
• Morphological and immunophenotypic analysis of breast carcinomas with basal and myoepithelial differentiation

  2006cited by this paper
• STEROIDRECEPTORSANDPROLIFERATIONIN THE HUMANBREAST Results and Discussion Distribution of ER in Normal Human Breast Lobules

  2006cited by this paper
• Locoregional relapse and distant metastasis in conservatively managed triple negative early-stage breast cancer.

  2006cited by this paper
• Prognostic Relevance of Basal Cytokeratin Expression in Operable Breast Cancer

  2006cited by this paper
• Multifactorial contributions to an acute DNA damage response by BRCA1/BARD1-containing complexes.

  2006cited by this paper
• Metaplastic Breast Carcinomas: Are They of Myoepithelial Differentiation?: Immunohistochemical Profile of the Sarcomatoid Subtype Using Novel Myoepithelial Markers

  2005cited by this paper
• Immunohistochemical identification of basal-type cytokeratins in invasive ductal breast carcinoma--relation with grade, stage, estrogen receptor and HER2.

  2005cited by this paper
• Exploiting the DNA repair defect in BRCA mutant cells in the design of new therapeutic strategies for cancer.

  2005cited by this paper
• The prognostic implication of the basal-like (cyclin Ehigh/ p27low/p53+glomeruloid-microvascular-proliferation +) phenotype of BRCA1-related breast cancer

  2005cited by this paper
• Isolation of a small molecule inhibitor of DNA base excision repair

  2005cited by this paper
• Re: Germline BRCA1 Mutations and a Basal Epithelial Phenotype in Breast Cancer

  2004cited by this paper
• Germline BRCA1 mutations and a basal epithelial phenotype in breast cancer.

  2004cited by this paper
• The Prognostic Implication of the Basal-Like (Cyclin Ehigh/p27low/p53+/Glomeruloid-Microvascular-Proliferation+) Phenotype of BRCA1-Related Breast Cancer

  2004cited by this paper
• BRCA1 and BRCA2: 1994 and beyond

  2004cited by this paper
• Oncogenic pathways in hereditary and sporadic breast cancer.

  2004cited by this paper
• Inhibition of the human apurinic/apyrimidinic endonuclease (APE1) repair activity and sensitization of breast cancer cells to DNA alkylating agents with lucanthone.

  2004cited by this paper
• Immunohistochemical and Clinical Characterization of the Basal-Like Subtype of Invasive Breast Carcinoma

  2004cited by this paper
• Loss of Bard1, the Heterodimeric Partner of the Brca1 Tumor Suppressor, Results in Early Embryonic Lethality and Chromosomal Instability

  2003cited by this paper
• Novel and Classic Myoepithelial/Stem Cell Markers in Metaplastic Carcinomas of the Breast

  2003cited by this paper
• Haplo-insufficiency of BRCA1 in sporadic breast cancer.

  2003cited by this paper
• The multiple nuclear functions of BRCA1: transcription, ubiquitination and DNA repair.

  2003cited by this paper
• Breast cancer classification and prognosis based on gene expression profiles from a population-based study

  2003cited by this paper
• Activation of the E3 ligase function of the BRCA1/BARD1 complex by polyubiquitin chains

  2002cited by this paper
• BRCA1 induces DNA damage recognition factors and enhances nucleotide excision repair

  2002cited by this paper
• Cancer susceptibility and the functions of BRCA1 and BRCA2.

  2002cited by this paper
• Autoubiquitination of the BRCA1·BARD1 RING Ubiquitin Ligase*

  2002cited by this paper
• Review Cancer Susceptibility and the Functions of BRCA1 and BRCA2

  2002cited by this paper
• Expression and prognostic significance of O6-methylguanine-DNA methyltransferase in hepatocellular, gastric, and breast cancers.

  2001cited by this paper
• BRCA1-induced large-scale chromatin unfolding and allele-specific effects of cancer-predisposing mutations

  2001cited by this paper
• Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications

  2001cited by this paper
• Expression and Prognostic Significance ofO6-Methylguanine-DNA Methyltransferase in Hepatocellular, Gastric, and Breast Cancers

  2001cited by this paper
• Direct DNA binding by Brca1

  2001cited by this paper
• BRCA1 and BRCA2 are necessary for the transcription-coupled repair of the oxidative 8-oxoguanine lesion in human cells.

  2000cited by this paper
• Molecular portraits of human breast tumours

  2000cited by this paper
• BASC, a super complex of BRCA1-associated proteins involved in the recognition and repair of aberrant DNA structures.

  2000cited by this paper
• Promoter hypermethylation and BRCA1 inactivation in sporadic breast and ovarian tumors.

  2000cited by this paper
• Methylation of the BRCA1 promoter region in sporadic breast and ovarian cancer: correlation with disease characteristics

  1999cited by this paper
• In Vitro Repression of Brca1-associated RING Domain Gene, Bard1, Induces Phenotypic Changes in Mammary Epithelial Cells

  1998cited by this paper
• BRCA1 required for transcription-coupled repair of oxidative DNA damage.

  1998cited by this paper

• Epigenetic alterations in triple-negative breast cancer and their clinical implications for diagnosis and therapy

  2025cites this paper
• Allelic Imbalance and Chromothripsis Lead to Diversity in Japanese Tumor Genomes With Whole‐Genome Duplication

  2025cites this paper
• TP53-specific mutations serve as a potential biomarker for homologous recombination deficiency in breast cancer: a clinical next-generation sequencing study

  2024cites this paper
• Unraveling the protein kinase C/NDRG1 signaling network in breast cancer

  2024cites this paper
• A high-throughput approach to identify BRCA1-downregulating compounds to enhance PARP inhibitor sensitivity

  2024cites this paper
• Combining PARP inhibitors and platinum-based chemotherapy in metastatic triple negative and/or BRCA-associated breast cancer

  2023cites this paper
• Loss of function of BRCA1 promotes EMT in mammary tumors through activation of TGFβR2 signaling pathway

  2022cites this paper
• Triple negative breast cancer: approved treatment options and their mechanisms of action

  2022cites this paper
• Deep exploration of PARP inhibitors in breast cancer: monotherapy and combination therapy

  2021cites this paper
• Concurrent Chemo-radiation As a Means of Achieving Pathologic Complete Response in Triple Negative Breast Cancer.

  2021cites this paper
• The Present and Future of the Treatment of Hereditary Breast Cancer

  2021cites this paper
• GATA3 functions downstream of BRCA1 to suppress EMT in breast cancer

  2021cites this paper
• A novel germline BRCA1 mutation identified in a family with hereditary breast and ovarian cancer syndrome

  2021cites this paper
• Targeting of lactate dehydrogenase C dysregulates the cell cycle and sensitizes breast cancer cells to DNA damage response targeted therapy

  2021cites this paper
• PARP1: Structural insights and pharmacological targets for inhibition.

  2021cites this paper
• PDGFRβ is an essential therapeutic target for BRCA1-deficient mammary tumors

  2021cites this paper
• UNDERSTANDING TRIPLE NEGATIVE BREAST CANCER: A REVIEW ON MOLECULAR SIGNALING PATHWAYS

  2020cites this paper
• A Preclinical Trial and Molecularly Annotated Patient Cohort Identify Predictive Biomarkers in Homologous Recombination–deficient Pancreatic Cancer

  2020cites this paper
• Discovery of Pamiparib (BGB-290), a Potent and Selective Poly (ADP-ribose) Polymerase (PARP) Inhibitor in Clinical Development.

  2020cites this paper
• N-glycosylated SGK196 suppresses the metastasis of basal-like breast cancer cells

  2020cites this paper
• Checkpoint Kinase 1 (CHK1) Inhibition Enhances the Sensitivity of Triple-Negative Breast Cancer Cells to Proton Irradiation via Rad51 Downregulation

  2020cites this paper
• Current and emerging biologic therapies for triple negative breast cancer

  2020cites this paper
• The Proliferative and Apoptotic Landscape of Basal-like Breast Cancer

  2019cites this paper
• Platinum Salts in Patients with Breast Cancer: A Focus on Predictive Factors

  2019cites this paper
• NEK10 tyrosine phosphorylates p53 and controls its transcriptional activity

  2019cites this paper
• How shall we treat early triple-negative breast cancer (TNBC): from the current standard to upcoming immuno-molecular strategies

  2018cites this paper
• Estrogen promotes estrogen receptor negative BRCA1-deficient tumor initiation and progression

  2018cites this paper
• Therapeutic Implications of the Molecular and Immune Landscape of Triple-Negative Breast Cancer

  2018cites this paper
• Synthetic Lethality of PARP Inhibition and Ionizing Radiation is p53-dependent

  2018cites this paper
• THE IMPACT OF HISTAMINE RECEPTOR 2 ANTAGONISTS ON BREAST CANCER DEVELOPMENT AND MONOCYTIC POPULATIONS

  2018cites this paper
• BRCA1/2‐negative hereditary triple‐negative breast cancers exhibit BRCAness

  2017cites this paper
• Predictive biomarkers for triple negative breast cancer treated with platinum-based chemotherapy

  2017cites this paper
• Triple negative breast cancer: the kiss of death

  2017cites this paper
• The role of BRCA status on prognosis in patients with triple-negative breast cancer

  2017cites this paper
• DNA damage repair in breast cancer and its therapeutic implications.

  2017cites this paper
• Impact of Etoposide on BRCA1 Expression in Various Breast Cancer Cell Lines

  2017influential citation
• Niraparib in ovarian cancer: results to date and clinical potential

  2017cites this paper
• TP53 Mutations in Breast and Ovarian Cancer.

  2017cites this paper
• Prognostic and Predictive Significance of Base Excision Repair in Human Cancers

  2017cites this paper
• The BRCA1 tumor suppressor: potential long-range interactions of the BRCA1 promoter and the risk of breast cancer

  2017cites this paper
• Inflammation and Nitrosative Stress Effects in Ovarian and Prostate Pathology and Carcinogenesis

  2017cites this paper
• Integrating c-Met molecular imaging into the optimisation of cancer therapy

  2016cites this paper
• Cytotoxic and targeted therapy for hereditary cancers

  2016cites this paper
• p16INK4a suppresses BRCA1-deficient mammary tumorigenesis

  2016cites this paper
• How interacting pathways are regulated by miRNAs in breast cancer subtypes

  2016cites this paper
• miR-151-5p, targeting chromatin remodeler SMARCA5, as a marker for the BRCAness phenotype

  2016cites this paper
• Performance of multiplicom's BRCA MASTR Dx kit on the detection of BRCA1 and BRCA2 mutations in fresh frozen ovarian and breast tumor samples

  2016cites this paper
• Iodinated benzimidazole PARP radiotracer for evaluating PARP1/2 expression in vitro and in vivo.

  2016cites this paper
• Application of RNAi-induced gene expression profiles for prognostic prediction in breast cancer

  2016cites this paper
• DNA-damaging autoantibodies and cancer: the lupus butterfly theory

  2016cites this paper
• Advances in PARP inhibitors for the treatment of breast cancer

  2015cites this paper
• Treating Triple-Negative Breast Cancer: Where Are We?

  2015cites this paper
• Molecular Medicine and Personalized Therapy for Breast Cancer Patients

  2015cites this paper
• Role of Carboplatin in the Treatment of Triple Negative Early- Stage Breast Cancer.

  2015cites this paper
• Synergistic suppressive effect of PARP-1 inhibitor PJ34 and HDAC inhibitor SAHA on proliferation of liver cancer cells

  2015cites this paper
• Niraparib: A Poly(ADP-ribose) Polymerase (PARP) Inhibitor for the Treatment of Tumors with Defective Homologous Recombination.

  2015cites this paper
• DNA damage response markers are differentially expressed in BRCA-mutated breast cancers

  2015cites this paper
• Comparative microRNA profiling of sporadic and BRCA1 associated basal-like breast cancers

  2015cites this paper
• DNA repair prognostic index modelling reveals an essential role for base excision repair in influencing clinical outcomes in ER negative and triple negative breast cancers

  2015cites this paper
• Design, synthesis and testing of novel anti-cancer agents targeting secretory pathway calcium ATPase

  2014cites this paper
• Lessons learned from the intrinsic subtypes of breast cancer in the quest for precision therapy

  2014cites this paper
• DNA Damage Response: From Tumourigenesis to Therapy

  2014cites this paper
• Pharmacogenomics and Personalized Medicine Dovepress Novel Treatment Strategies in Triple-negative Breast Cancer: Specific Role of Poly(adenosine Diphosphate-ribose) Polymerase Inhibition

  year unknowncites this paper